We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-1.62%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.99B
AUM Growth
-$546M
Cap. Flow
-$71.8M
Cap. Flow %
-2.4%
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$131M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$75.7M
3
IGMS
IGM Biosciences
IGMS
+$63.5M
4
ALLK
Allakos
ALLK
+$51.3M
5
NVRO
NEVRO CORP.
NVRO
+$48.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$405M
2
EHTH icon
eHealth
EHTH
+$76.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$62.6M
4
ELV icon
Elevance Health
ELV
+$51.8M
5
UNH icon
UnitedHealth
UNH
+$34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Miscellaneous 0.93%
3 Energy 0.01%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
76
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-97,191
Closed -$8.32M
EHTH icon
77
eHealth
EHTH
$38.4M
– –
-888,705
Closed -$76.5M
ELV icon
78
Elevance Health
ELV
$85.5B
– –
-183,500
Closed -$51.8M
PSNL icon
79
Personalis
PSNL
$1.82B
– –
-400,000
Closed -$10.9M
SRPT icon
80
Sarepta Therapeutics
SRPT
$2.2B
– –
-412,000
Closed -$62.6M
TDOC icon
81
Teladoc Health
TDOC
$1.18B
– –
-461,880
Closed -$30.7M
ONC
82
BeOne Medicines Ltd
ONC
$41.5B
– –
-39,900
Closed -$4.95M
MOR
83
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-733,699
Closed -$17.7M
NVTA
84
DELISTED
Invitae Corporation
NVTA
– –
-375,375
Closed -$8.82M
JNCE
85
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-254,590
Closed -$1.26M
GBT
86
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-188,000
Closed -$9.89M
OXFD
87
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-1,796,477
Closed -$24.7M
AVDR
88
DELISTED
Avedro, Inc Common Stock
AVDR
– –
-216,200
Closed -$4.25M
ARRY
89
DELISTED
Array Biopharma Inc
ARRY
– –
-8,752,254
Closed -$405M
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2019 Portfolio in Review

As of Q3 2019, Redmile Group held 90 positions worth $2.99B, down 15% from $3.53B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q3 2019 filing shows 10 new, 29 increased, 22 reduced and 16 closed positions. Its largest new stake was Alexion Pharmaceuticals: 1,162,200 shares worth $114M. The largest sale was Array Biopharma Inc, an estimated $405M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Energy.

  • Redmile Group's largest Q3 2019 buy was Alexion Pharmaceuticals: 1,162,200 shares worth $114M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019, an estimated $75.7M increase.
  • Redmile Group's biggest Q3 2019 reduction was UnitedHealth, cutting an estimated $34M.
  • Redmile Group fully exited Array Biopharma Inc in Q3 2019, selling an estimated $405M.
  • Redmile Group's ten largest holdings make up 49% of its $2.99B portfolio in Q3 2019.
  • Redmile Group opened 10 new positions and closed 16 in Q3 2019.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $2.99B.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.